Key:
C = CALGB
E = ECOG
N = NSABP
P = Pharmacy
R = RTOG
S = SWOG
CTSU= NCI Cancer Trials Support Unit
V = Vermont Cancer Center
Updated 8/26/10
Anemia:
CTSU E2905
- Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and
in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Breast:
N B41
- A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable & Operable HER2+ Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab & to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
N B43
- A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
N B44
- A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients
with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy
PlusTrastuzumab Plus Bevacizumab
N B46
- A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizimab to TC Alone and to TAC for Women with Node-Positive or High Risk Node-Negative, HER2-Negative Breast Cancer
C 40502
- A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone combined with bevacizumab as 1st line therapy for locally recurrent or metastatic breast cancer
C 40603
- Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer.
CTSU PACCT-1
- Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
CTSU N0733
- Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
CTSU S0500
- A randomized phase III trial to test the strategy of changing therapy vs. maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment
V 0308
- Clinical and Molecular Markers of Breast Cancer Risk – Blood and Tissue Collection
V 0407
- Statins and Breast Cancer Biomarkers: Evaluation of Breast Density and Serum Biomarkers in Response to Statin Administration
Bladder:
C 90601
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
Colorectal:
C 80702
- A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
N R-04
- A trial comparing pre-op RT and Capecitabine with pre-op RT and continuous IV infusion (CVI) of 5FU in the treatment of patients with operable rectal cancer
N C-11
- A Phase III Study Evaluating the Role of Perioperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases.
CTSU SO600
- Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX.
Gastric/Gastroestroesophageal:
CTSU-RTOG-0436
- Phase III Trial evaluating the addition of Cetuximab to Paclitaxel, Cisplatin and RT for Patients with esophageal cancer who are treated without surgery
Head & Neck:
CTSU E-1305
- A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer
Leukemia:
C 8461
- Mandatory Companion Study for Other Protocols; Cytogenetics
C 9665
- Mandatory Companion Study for Other Protocols; Tissue Banking
C 10602
- A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
C 29801
- Mandatory Companion Study for Other Protocols; Molecular Maonitoring in CML
Liver:
C 80802
- Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
Lung: SCLC Limited:
C 30610
- Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
Lung: SCLC Extensive:
C 30504
- Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study
Lung: NSCLC Limited:
CTSU-E1505
- A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
Lung: NSCLC Stage III:
C 30605
- A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-small Cell Lung Cancer
***Temp. Suspension***
Lung: NSCLC Advanced:
C 30704
- A randomized phase II study to assess the efficacy of Premetrexed or Sunitinib or Pemetrexed plus Sunitinib in 2nd line treatment of advanced NSCLC
C 30607
- Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
CTSU-SO819
- A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer
C 30801
- A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Lymphoma:
C 50303
- Phase III randomized study of R-CHOP vs. dose-adjusted EPOCH-R with molecular profiling in untreated DeNovo diffuse large B-cell lymphomas
C 50401
- A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid™, CC-5013) (IND # 73034) vs. Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) After Relapse from a Rituximab-Containing Combination Regimen
C 50803
- A Phase II Trial of Lenalidomide (Revlimid) plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma
Melanoma:
CTSU-E1697
- Phase III Randomized Study of Four Weeks High Dose
IFN-α2b in Stage T2b No, T3a-bN0, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma
Neuropathy:
CALGB-170601
- A phase III double blind trial of oral Duloxetine for treatment of pain associated with chemotherapy induced peripheral neuropathy study (CIPN)
Other:
C 70604
A randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Prostate:
CTSU E-3805
- CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer
Renal:
CTSU E-2804
- The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
Prevention Trials:
N P-5
- Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
